Cargando…

Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells

BACKGROUND: Effective treatment of prostate cancer should be based on targeting interactions between tumour cell signalling pathways and key converging downstream effectors. Here, we determined how the tumourigenic phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), tumour-suppressive phosphatase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dixon, K M, Lui, G Y L, Kovacevic, Z, Zhang, D, Yao, M, Chen, Z, Dong, Q, Assinder, S J, Richardson, D R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566801/ https://www.ncbi.nlm.nih.gov/pubmed/23287991 http://dx.doi.org/10.1038/bjc.2012.582

Ejemplares similares

Proteolytic cleavage and truncation of NDRG1 in human prostate cancer cells, but not normal prostate epithelial cells
por: Ghalayini, Mohammad K., et al.
Publicado: (2013)

The metastasis suppressor NDRG1 directly regulates androgen receptor signaling in prostate cancer
por: Lim, Syer C., et al.
Publicado: (2021)

Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: two saturable mechanisms of Dp44mT uptake by cells
por: Merlot, Angelica M., et al.
Publicado: (2015)

The tumour suppressor miR-34c targets MET in prostate cancer cells
por: Hagman, Z, et al.
Publicado: (2013)

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer
por: Ahmad, I, et al.
Publicado: (2013)

ERK5 signalling in prostate cancer promotes an invasive phenotype
por: Ramsay, A K, et al.
Publicado: (2011)

The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion
por: Sharma, Anup, et al.
Publicado: (2017)

The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-Myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway
por: Wang, Jiabei, et al.
Publicado: (2014)

Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells
por: Sun, Z-J, et al.
Publicado: (2008)

The metastasis suppressor, NDRG1, inhibits “stemness” of colorectal cancer via down-regulation of nuclear β-catenin and CD44
por: Wangpu, Xiongzhi, et al.
Publicado: (2015)

TGFβ-induced phosphorylation of Par6 promotes migration and invasion in prostate cancer cells
por: Mu, Y, et al.
Publicado: (2015)

Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer
por: Angst, E, et al.
Publicado: (2006)

Editorial: Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques
por: Drummen, Gregor P. C., et al.
Publicado: (2016)

The TGF-β signalling negative regulator PICK1 represses prostate cancer metastasis to bone
por: Dai, Yuhu, et al.
Publicado: (2017)

Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis
por: Willis, Sarah R, et al.
Publicado: (2014)

The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
por: Avgeris, M, et al.
Publicado: (2013)

A mechanism for overcoming P-glycoprotein-mediated drug resistance: novel combination therapy that releases stored doxorubicin from lysosomes via lysosomal permeabilization using Dp44mT or DpC
por: Seebacher, Nicole A, et al.
Publicado: (2016)

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
por: Cuzick, J, et al.
Publicado: (2013)

Valproic acid inhibits the invasion of PC3 prostate cancer cells by upregulating the metastasis suppressor protein NDRG1
por: Lee, Jae Eun, et al.
Publicado: (2015)

Impaired access of lymphocytes to neoplastic prostate tissue is associated with neoangiogenesis in the tumour site
por: Fedida, S, et al.
Publicado: (2007)

Letter to the Editor: “Analysis of the Interaction of Dp44mT with Human Serum Albumin and Calf Thymus DNA Using Molecular Docking and Spectroscopic Techniques”
por: Merlot, Angelica M., et al.
Publicado: (2016)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

The Iron Chelator, Dp44mT, Effectively Inhibits Human Oral Squamous Cell Carcinoma Cell Growth in Vitro and in Vivo
por: Lee, Jehn-Chuan, et al.
Publicado: (2016)

The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1
por: Liu, Wensheng, et al.
Publicado: (2015)

Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer
por: Baron, V T, et al.
Publicado: (2015)

Tumor suppressor NDRG2 tips the balance of oncogenic TGF-β via EMT inhibition in colorectal cancer
por: Shen, L, et al.
Publicado: (2014)

Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate
por: Elkahwaji, J E, et al.
Publicado: (2009)

Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin β1-ERK pathway
por: Han, S, et al.
Publicado: (2014)

Copper-Catalyzed Glutathione Oxidation is Accelerated by the Anticancer Thiosemicarbazone Dp44mT and Further Boosted at Lower pH
por: Falcone, Enrico, et al.
Publicado: (2022)

Re-Shaping the Pancreatic Cancer Tumor Microenvironment: A New Role for the Metastasis Suppressor NDRG1
por: Chang, Jiawei, et al.
Publicado: (2023)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression
por: Hao, J, et al.
Publicado: (2010)

A Promising Future for Prostate Cancer Diagnostics
por: Assinder, Stephen J., et al.
Publicado: (2017)

Cellular changes in boric acid-treated DU-145 prostate cancer cells
por: Barranco, W T, et al.
Publicado: (2006)

microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer
por: Ueno, K, et al.
Publicado: (2013)

Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1
por: Geleta, Bekesho, et al.
Publicado: (2022)

Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells
por: McPherson, R A C, et al.
Publicado: (2009)

MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker
por: Goto, Yusuke, et al.
Publicado: (2015)

Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
por: Giskeødegård, Guro F, et al.
Publicado: (2015)

NDRG1 in Cancer: A Suppressor, Promoter, or Both?
por: Joshi, Vaibhavi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dinhtq7iv9jf54btju5ledpp2k